Washington
Ended · Crossroads Q3 2026Lobbying Q3 None last Q1 2026
YoY n/a vs Q3 2025
Members 0 90 days
Buys / sells 0 / 0 0 trades
MMMMedicare/Medicaid
8 quarters Open in Washington ›
APMD
Apnimed, Inc.$18.95 −0.04 (−0.21%)
Oct 26 4:00 PM ET · prev $18.99
Market cap
$771.4M
Small cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
$50.00
+164% · range $41.00–60.00
Since first trade
−24.2%
from $25.00 · Jul 31
30 days
−12.6%
from $21.67
Range since listing
$16.60–32.55
−42% from high · low Oct 19
Avg volume 20D
415.0K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$5.2M
2 buyers · 0 sellers · since Aug 3
Filing reports
6
analyzed by SecBot
SecBot read BULLISH 5 reports · 90 days
Balance 0 bearish · 3 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 5/5 ·Next FDA decision date, Feb 28, 2027
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- B Aug 3 2 insiders buy $5.2M at $16.00
- E Aug 3 Offering: Apnimed Announces Closing of Upsized Initial Public Offeri…
- R Aug 3 Director Paul J. Sekhri made a $200K open-market purchase of APMD at…
- R Aug 5 Apnimed insiders executed a $5.2M cluster buy on 2026-08-03 at $16/s…
- A Aug 25 4 analysts initiate
- X Aug 31 Short interest jumps 38.6% to 564.8K
- X Sep 15 Short interest jumps 55.7% to 879.7K
- X Sep 30 Short interest jumps 100.6% to 1.76M
Signal stack
Where each data set points today.
- InsidersBULLISH
2 insiders bought $5.2M. No open-market sales.
- AnalystsBULLISH
9 of 10 rate it Buy or better. Every target is above the price.
- TrendDOWNTREND
21% below its 50-day average.
The Street
10 analysts 90% rate it Buy or better
12-month targets · 3 analysts
$18.95 $41.00 $50.00 $60.00
Price is below the lowest target. Median implies +164%.Targets as of Oct 27, 2026.
Recent actions
| Date | Firm | Rating |
|---|---|---|
| Aug 25, 2026 | LifeSci Capital INITIATE | Outperform |
| Aug 25, 2026 | Cantor Fitzgerald INITIATE | Overweight |
| Aug 25, 2026 | Evercore ISI Group INITIATE | Outperform |
| Aug 25, 2026 | B of A Securities INITIATE | Buy |
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent
Oct 2, 2026
Press release
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical…
Sep 30, 2026
Short interest
Short Interest: APMD up 101% to 1.8M shares
Settlement 2026-09-30 | Days to cover: 2.09 | ≈4.24% of shares outstanding (est.)
Sep 11, 2026
Clinical Trial
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)
Phase 3 · COMPLETED
Sep 8, 2026
Earnings
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company…
Sep 4, 2026
Press release
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late stage clinical pharmaceutical…
Insider ledger
Form 4$5.2M
bought · 2 insiders
$0
sold · 0 insiders
| Date | Insider | Type | Value |
|---|---|---|---|
| Aug 3, 2026 | Alpha Wave Ventures GP, Ltd 10%+ Owner | CONVERT | 21,779,726 sh |
| Aug 3, 2026 | Alpha Wave Ventures GP, Ltd 10%+ Owner | CONVERT | 5,404,918 sh |
| Aug 3, 2026 | Alpha Wave Ventures GP, Ltd 10%+ Owner | CONVERT | 4,006,611 sh |
| Aug 3, 2026 | Alpha Wave Ventures GP, Ltd 10%+ Owner | CONVERT | 1,351,227 sh |
| Aug 3, 2026 | Morningside Venture Investments Ltd 10%+ Owner | OTHER | 75,624 sh |
| Aug 3, 2026 | Alpha Wave Ventures GP, Ltd 10%+ Owner | CONVERT | 720,655 sh |
| Aug 3, 2026 | Alpha Wave Ventures GP, Ltd 10%+ Owner | CONVERT | $20.4M |
| Aug 3, 2026 | Morningside Venture Investments Ltd 10%+ Owner | CONVERT | 1,088,986.3 sh |
Earnings setup
Estimates−$0.60
EPS estimate, this quarter
Current-quarter EPS estimate
$0.00090d
$0.00060d
−$0.60030d
−$0.6007d
−$0.600Now
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.60 | -$0.61–-$0.59 | +0.0% | $0.00 |
| Next Q | -$0.72 | -$0.80–-$0.64 | +0.0% | $0.00 |
| Current FY | -$0.06 | -$0.06–-$0.06 | — | $90.8M |
| Next FY | -$3.98 | -$5.55–-$1.39 | +0.0% | $22.4M |
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short
Trading halts
| Jul 31, 2026 | Volatility Pause | Resumed |
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 Other
Aug 5, 2026 SEC Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “
Apnimed insiders executed a $5.2M cluster buy on 2026-08-03 at $16/share, led by 10% owner Morningside Venture ($5M)…
CLUSTER — Impact 7/10
Director Paul J. Sekhri made a $200K open-market purchase of APMD at $16/share on August 3, 2026, alongside a large…
INSIDER-BUY — Impact 7/10
Aug 3, 2026 Insider
Alpha Wave Ventures GP, Ltd disposed of 21,779,726 shares
10%+ Owner
Aug 3, 2026 Insider
Alpha Wave Ventures GP, Ltd disposed of 5,404,918 shares
10%+ Owner
Aug 3, 2026 Insider
Jul 31, 2026 SEC Alpha Wave Ventures GP, Ltd acquired 4,006,611 shares
10%+ Owner
Apnimed priced its IPO of 12,000,000 shares at $16.00 per share, at the top of the $14-$16 range, raising $192.0…
424B4 — Impact 6/10
SecBot reports
6 filings · 3 bullish · 0 bearish · 1 mixed · 2 neutral- BULLISH CLUSTERAug 5, 2026
Apnimed insiders executed a $5.2M cluster buy on 2026-08-03 at $16/share, led by 10% owner…
The $5.2M cluster buy from Apnimed's largest holder and a director, with zero informative sales, strongly signals confidence ahead of a potential catalyst (e.g., FDA decision, Phase 3 trial data, or…
- BULLISH INSIDER-BUYAug 3, 2026
Director Paul J. Sekhri made a $200K open-market purchase of APMD at $16/share on August 3, 2026…
The combination of a director's $200K buy, a $5M open-market purchase by a major venture holder, and a $20.4M cash derivative conversion by another large investor on the same day represents an…
- MIXED 424B4Jul 31, 2026
Apnimed priced its IPO of 12,000,000 shares at $16.00 per share, at the top of the $14-$16 range…
The IPO at the top of the range signals strong institutional demand. The key catalyst is the FDA decision on Oxnimbi by February 28, 2027. Monitor for FDA advisory committee meetings, any clinical…
- BULLISH EFFECTJul 31, 2026
The SEC declared effective Apnimed's S-1 registration statement for its IPO on July 30, 2026. The…
The IPO is now effective; expect pricing and first trading day within 1-2 days. Monitor for the final pricing announcement and initial trading performance. The upcoming PDUFA date in February 2027…
All APMD filing & press-release reports (6)
- CLUSTER reportAug 5, 2026
- INSIDER-BUY reportAug 3, 2026
- 424B4 reportJul 31, 2026
- EFFECT reportJul 31, 2026
- 3 reportJul 30, 2026
- S-1/A reportJul 27, 2026